Mavacamten is the first and only FDA-approved cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (HCM). An important factor to the success of the VALOR HCM trial was the participation of specialized cardiac sonographers and imagers.
Milind Desai, MD, MBA speaks with Jeanne Drinko, Amy Kanta and Anne Campbell about the importance of cardiac imaging.


Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162

Clinicians should consider statin therapy for primary prevention. Vikas Sunder, MD, a cardiologist in Preventive Cardiology, reviews indicators and considerations for statin initiation as well as barriers to adherence.

Learn more about the Section of Preventive Cardiology and Rehabilitation
https://my.clevelandclinic.org/departments/heart/depts/preventive-cardiology-rehabilitation

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162

Roy Chung, MD sits down with Thomas Callahan, MD to talk about the challenges of left bundle branch area pacing, particularly management after implant. Dr. Chung has much experience with conduction system pacing and shares his experience during this podcast.

Learn more about Cleveland Clinic's Pacemaker and Defibrillator Lead Extraction Center
https://my.clevelandclinic.org/departments/heart/depts/pacemaker-defibrillator

Interested in learning more about lead management? Join experts in the field at LEADconnection.
https://leadconnection.org/